Published in Cancer Weekly, March 23rd, 2004
Nipent is currently approved as a single-agent treatment for patients with hairy cell leukemia and under investigational study for a number of hematological malignancies. Terms of the transaction were not disclosed.
In 1996, SuperGen purchased domestic distribution and marketing rights to Nipent from the Warner-Lambert Company, which was later acquired by Pfizer.
"As a result of this transaction with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.